Advertisement

Anti-leukemia activity of 4-amino-2-aryl-6,9-dichlorobenzo[g]pteridines

  • Antonio J. Ruiz-AlcarazEmail author
  • Violeta Carmona-Martínez
  • Antonio Guirado
  • Jesús Gálvez
  • María Martínez-Esparza
  • Pilar García-PeñarrubiaEmail author
Original Article

Abstract

Pteridines are bicyclic heterocyclic compounds with a pyrazino[2,3-d]pyrimidine nucleus that have shown a wide range of therapeutic utilities. Concretely, 4-aminopteridine derivatives have demonstrated both anti-inflammatory and anti-cancer properties, and some of them, such as methotrexate, are profusely used in medical practice. We have recently synthesized and tested the biological activity of a novel series of 4-amino-2-aryl-6,9-dichlorobenzo[g]pteridines, finding that they present anti-inflammatory properties, as they were able to inhibit in vitro the production of pro-inflammatory cytokines TNF-α and IL-6. Now, we have evaluated the anti-tumor potential of these compounds on HL-60 and K562 leukemia cell lines. Cells growing at exponential rate were exposed to decreasing doses of each compound, from 50 to 0.39 μM, for 24, 48, and 72 h. Cell viability was tested by MTT assay and cell death fashion determined by annexin V/propidium iodide assay. The cytotoxicity of the compounds was determined in differentiated macrophage-like HL-60 cells and in human peripheral blood mononuclear cells to evaluate the potential side effects on quiescent tumor cells and normal cells, respectively. Among the series, compounds 1a, 1b, 1g, 1j, and 1k showed anti-proliferative activity. Compounds 1j and 1k were active against both HL-60 and K562 cells, with a lower IC50 against HL-60 cells. Compounds 1a, 1b, and 1g had a great cytotoxic activity against HL-60, but they were far less potent against K562 cells. None had side effects in differentiated tumor cells or in human peripheral blood mononuclear cells. In conclusion, our results demonstrate that some compounds of this series of 4-amino-2-aryl-6,9-dichlorobenzo[g]pteridines have anti-cancer properties in vitro.

Keywords

Pteridine derivatives Anti-tumor drugs Anti-proliferative agents Late apoptosis Necrosis 

Notes

Author contributions

AJRA conceived and designed the experimental plan, performed experiments, analyzed the data, and wrote the manuscript. VCM performed experiments, analyzed the data and wrote the manuscript. AG synthesized and provided the new organic compounds and wrote the manuscript. JG analyzed data. MME wrote the manuscript. PGP provided the necessary facilities and wrote the manuscript. All authors read and approved the manuscript.

Funding information

This study was partially supported by a grant from the Fundación Séneca of the Comunidad Autónoma de la Región de Murcia (project 19249/PI/14), Spain. Violeta Carmona-Martínez was supported by the Dirección General de Investigación Científica y Técnica (Grant EJ-2014-A-95803), Spain.

Compliance with ethical standards

The ethics committees (Comité Ético de Investigación Clínica del Hospital Universitario Virgen de la Arrixaca, and Comité de Bioética de la Universidad de Murcia) approved the study protocol according to the 1975 Declaration of Helsinki.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

210_2018_1587_MOESM1_ESM.docx (13 kb)
Supplementary Table 1 (DOCX 13 kb)

References

  1. Abolmaali SS, Tamaddon AM, Dinarvand R (2013) A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. Cancer Chemother Pharmacol 71:1115–1130.  https://doi.org/10.1007/s00280-012-2062-0 CrossRefPubMedGoogle Scholar
  2. Carmona-Martínez V, Ruiz-Alcaraz AJ, Vera M, Guirado A, Martínez-Esparza M, García-Peñarrubia P (2018) Therapeutic potential of pteridine derivatives: a comprehensive review. Med Res Rev.  https://doi.org/10.1002/med.21529
  3. Cheng B, Liu I-F, Tse-Dinh Y-C (2007) Compounds with antibacterial activity that enhance DNA cleavage by bacterial DNA topoisomerase I. J Antimicrob Chemother 59:640–645.  https://doi.org/10.1093/jac/dkl556 CrossRefPubMedGoogle Scholar
  4. Chiu C-F, Bai L-Y, Kapuriya N, Peng SY, Wu CY, Sargeant AM, Chen MY, Weng JR (2014) Antitumor effects of BI-D1870 on human oral squamous cell carcinoma. Cancer Chemother Pharmacol 73:237–247.  https://doi.org/10.1007/s00280-013-2349-9 CrossRefPubMedGoogle Scholar
  5. De Jonghe S, Marchand A, Gao L-J et al (2011) Synthesis and in vitro evaluation of 2-amino-4-N-piperazinyl-6-(3,4-dimethoxyphenyl)-pteridines as dual immunosuppressive and anti-inflammatory agents. Bioorg Med Chem Lett 21:145–149.  https://doi.org/10.1016/j.bmcl.2010.11.053 CrossRefPubMedGoogle Scholar
  6. Ding Y, Girardet J-L, Smith KL, Larson G, Prigaro B, Lai VCH, Zhong W, Wu JZ (2005) Parallel synthesis of pteridine derivatives as potent inhibitors for hepatitis C virus NS5B RNA-dependent RNA polymerase. Bioorg Med Chem Lett 15:675–678.  https://doi.org/10.1016/j.bmcl.2004.11.028 CrossRefPubMedGoogle Scholar
  7. El-Sabbagh OI, El-Sadek ME, El-Kalyoubi S, Ismail I (2007) Synthesis, DNA binding and antiviral activity of new uracil, xanthine, and pteridine derivatives. Arch Pharm (Weinheim) 340:26–31.  https://doi.org/10.1002/ardp.200600149 CrossRefGoogle Scholar
  8. Guirado A, López S, Ruiz-Alcaraz AJ et al (2012) Synthesis and biological evaluation of 4-alkoxy-6,9-dichloro[1,2,4] triazolo[4,3-a] quinoxalines as inhibitors of TNF-α and IL-6. Eur J Med Chem 54:87–94.  https://doi.org/10.1016/j.ejmech.2012.04.035 CrossRefPubMedGoogle Scholar
  9. Guirado A, López Sánchez JI, Bautista D (2011) Reactions of 5,8-dichloro-2,3-dicyanoquinoxaline with amines and hydrazines. A new and efficient synthetic approach to 3-amino-5,8-dichloroflavazoles. Tetrahedron 67:4123–4129.  https://doi.org/10.1016/j.tet.2011.03.104 CrossRefGoogle Scholar
  10. Guirado A, López Sánchez JI, Ruiz-Alcaraz AJ, García-Peñarrubia P, Bautista D, Gálvez J (2013) First synthesis and biological evaluation of 4-amino-2-aryl-6,9-dichlorobenzo [g] pteridines as inhibitors of TNF-α and IL-6. Eur J Med Chem 66:269–275.  https://doi.org/10.1016/j.ejmech.2013.05.020 CrossRefPubMedGoogle Scholar
  11. Gupta D, Shah HP, Malu K et al (2014) Differentiation and characterization of myeloid cells. Curr Protoc Immunol 104:Unit 22F.5.  https://doi.org/10.1002/0471142735.im22f05s104 CrossRefPubMedPubMedCentralGoogle Scholar
  12. Kośliński P, Bujak R, Daghir E, Markuszewski MJ (2011) Metabolic profiling of pteridines for determination of potential biomarkers in cancer diseases. Electrophoresis 32:2044–2054.  https://doi.org/10.1002/elps.201000664 CrossRefPubMedGoogle Scholar
  13. Li M-H, Choi SK, Thomas TP, Desai A, Lee KH, Kotlyar A, Banaszak Holl MM, Baker JR Jr (2012) Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting. Eur J Med Chem 47:560–572.  https://doi.org/10.1016/j.ejmech.2011.11.027 CrossRefPubMedGoogle Scholar
  14. Ma F, Lü G, Zhou W-F, Wang QJ, Zhang YH, Yao QZ (2009) Synthesis and biological activities of 2,4-diaminopteridine derivatives. Arch Pharm (Weinheim) 342:274–280.  https://doi.org/10.1002/ardp.200800192 CrossRefGoogle Scholar
  15. Marques SM, Enyedy EA, Supuran CT, Krupenko NI, Krupenko SA, Amélia Santos M (2010) Pteridine-sulfonamide conjugates as dual inhibitors of carbonic anhydrases and dihydrofolate reductase with potential antitumor activity. Bioorg Med Chem 18:5081–5089.  https://doi.org/10.1016/j.bmc.2010.05.072 CrossRefPubMedGoogle Scholar
  16. Mullice LA, Mottram HJ, Hallett AJ, Pope SJA (2012) Gold(I) complexes incorporating emissive mercapto-pteridine ligands: syntheses, X-ray structure, luminescence and preliminary cytotoxic evaluation. Eur J Inorg Chem 2012:3054–3060.  https://doi.org/10.1002/ejic.201200147 CrossRefGoogle Scholar
  17. Nelson ME, Loktionova NA, Pegg AE, Moschel RC (2004) 2-Amino-O4-benzylpteridine derivatives: potent inactivators of O6-alkylguanine-DNA alkyltransferase. J Med Chem 47:3887–3891.  https://doi.org/10.1021/jm049758 CrossRefPubMedGoogle Scholar
  18. Palanki MSS, Dneprovskaia E, Doukas J, Fine RM, Hood J, Kang X, Lohse D, Martin M, Noronha G, Soll RM, Wrasidlo W, Yee S, Zhu H (2007) Discovery of 3,3′-(2,4-diaminopteridine-6,7-diyl) diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction. J Med Chem 50:4279–4294.  https://doi.org/10.1021/jm051056c CrossRefPubMedGoogle Scholar
  19. Pontiki E, Hadjipavlou-Litina D, Patsilinakos A, Tran TM, Marson CM (2015) Pteridine-2,4-diamine derivatives as radical scavengers and inhibitors of lipoxygenase that can possess anti-inflammatory properties. Future Med Chem 7:1937–1951.  https://doi.org/10.4155/fmc.15.104 CrossRefPubMedPubMedCentralGoogle Scholar
  20. Prins LHA, Petzer JP, Malan SF (2009) Synthesis and in vitro evaluation of pteridine analogues as monoamine oxidase B and nitric oxide synthase inhibitors. Bioorg Med Chem 17:7523–7530.  https://doi.org/10.1016/j.bmc.2009.09.019 CrossRefPubMedGoogle Scholar
  21. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, Adolf GR (2009) BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 15:3094–3102.  https://doi.org/10.1158/1078-0432.CCR-08-2445 CrossRefPubMedGoogle Scholar
  22. Ruiz-Alcaraz AJ, Tapia-Abellán A, Fernández-Fernández MD, Tristán-Manzano M, Hernández-Caselles T, Sánchez-Velasco E, Miras-López M, Martínez-Esparza M, García-Peñarrubia P (2016) A novel CD14(high) CD16(high) subset of peritoneal macrophages from cirrhotic patients is associated to an increased response to LPS. Mol Immunol 72:28–36.  https://doi.org/10.1016/j.molimm.2016.02.012 CrossRefPubMedGoogle Scholar
  23. Ruiz-Alcaraz AJ, Tristán-Manzano M, Guirado A, Gálvez J, Martínez-Esparza M, García-Peñarrubia P (2017) Intracellular signaling modifications involved in the anti-inflammatory effect of 4-alkoxy-6,9-dichloro[1,2,4]triazolo[4,3-a] quinoxalines on macrophages. Eur J Pharm Sci 99:292–298.  https://doi.org/10.1016/j.ejps.2016.12.037 CrossRefPubMedGoogle Scholar
  24. Sun D, Yang Y, Lyu J et al (2016) Discovery and rational design of pteridin-7(8H)-one-based inhibitors targeting FMS-like tyrosine kinase 3 (FLT3) and its mutants. J Med Chem 59:6187–6200.  https://doi.org/10.1021/acs.jmedchem.6b00374 CrossRefPubMedGoogle Scholar
  25. Tandon M, Salamoun JM, Carder EJ, Farber E, Xu S, Deng F, Tang H, Wipf P, Wang QJ (2015) SD-208, a novel protein kinase D inhibitor, blocks prostate cancer cell proliferation and tumor growth in vivo by inducing G2/M cell cycle arrest. PLoS One 10:e0119346.  https://doi.org/10.1371/journal.pone.0119346 CrossRefPubMedPubMedCentralGoogle Scholar
  26. Tristán-Manzano M, Guirado A, Martínez-Esparza M et al (2015) Quinoxalines potential to target pathologies. Curr Med Chem 22:3075–3108CrossRefGoogle Scholar
  27. Wang H, Yang C, Doherty JR, Roush WR, Cleveland JL, Bannister TD (2014) Synthesis and structure-activity relationships of pteridine dione and trione monocarboxylate transporter 1 inhibitors. J Med Chem 57:7317–7324.  https://doi.org/10.1021/jm500640x CrossRefPubMedPubMedCentralGoogle Scholar
  28. Zhang Z, Wu J, Ran F, Guo Y, Tian R, Zhou S, Wang X, Liu Z, Zhang L, Cui J, Liu J (2009) Novel 8-deaza-5,6,7,8-tetrahydroaminopterin derivatives as dihydrofolate inhibitor: design, synthesis and antifolate activity. Eur J Med Chem 44:764–771.  https://doi.org/10.1016/j.ejmech.2008.04.017 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Departamento de Bioquímica, Biología Molecular (B) e Inmunología, School of Medicine, IMIB and Regional Campus of International Excellence “Campus Mare Nostrum”Universidad de MurciaMurciaSpain
  2. 2.Departamento de Química OrgánicaUniversidad de Murcia, Campus de EspinardoMurciaSpain
  3. 3.Departamento de Química FísicaUniversidad de Murcia, Campus de EspinardoMurciaSpain

Personalised recommendations